
|Articles|September 1, 2016
- Pharmaceutical Executive-09-01-2016
- Volume 36
- Issue 9
Pharmaceutical Executive, September 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
Pharm Exec's Emerging Pharma Leaders 2016over 9 years ago
Emerging Leaders 2016: Lessons from the Front Benchover 9 years ago
Patient-Centered Strategies for Clinical Trials & Treatmentover 9 years ago
Rise of the Vox Populiover 9 years ago
Opioid Epidemic Prompts More Finger Pointing at Pharmaover 9 years ago
Country Report: France, Part IINewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade
2
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
3
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
4
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
5




